Urbini Milena, Astolfi Annalisa, Indio Valentina, Nannini Margherita, Pizzi Carmine, Paolisso Pasquale, Tarantino Giuseppe, Pantaleo Maria Abbondanza, Saponara Maristella
"Giorgio Prodi" Cancer Research Center, University of Bologna, Bologna, Italy.
Department of Specialized, Experimental and Diagnostic Medicine, Medical Oncology Unit, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Ther Adv Med Oncol. 2020 May 18;12:1758835920918492. doi: 10.1177/1758835920918492. eCollection 2020.
Cardiac tumors are rare and complex entities. Early assessment and differentiation between non-neoplastic and neoplastic masses, be they benign or malignant, is essential for guiding diagnosis, determining prognosis, and planning therapy. Cardiac sarcomas represent the most frequent primary malignant histotype. They could have manifold presentations so that the diagnosis is often belated. Moreover, considering their rarity and the limitation due to the cardiac location itself, the optimal multimodal management of patients affected by primary cardiac sarcomas still remains highly difficult and outcome dismal. Therefore, there is an urgent need to improve these results mainly focusing on more adequate tools for prompt diagnosis and exploring new and more effective therapies. Knowledge about the molecular landscape and pathogenesis of cardiac sarcoma is even more limited due to the rarity of this disease. In this sense, the molecular characterization of heart tumors could unfold potentially novel, druggable targets. In this review, we focused on genetic aberrations and molecular biology of cardiac sarcomas, collecting the scarce information available and resuming all the molecular findings discovered in each tumor subtype, with the aim to get further insights on mechanisms involved in tumor growth and to possibly highlight specific molecular profiles that can be used as diagnostic tests and unveil new clinically actionable targets in this tricky and challenging disease.
心脏肿瘤是罕见且复杂的疾病。早期评估以及区分非肿瘤性和肿瘤性肿块,无论其为良性还是恶性,对于指导诊断、确定预后和规划治疗至关重要。心脏肉瘤是最常见的原发性恶性组织学类型。它们可能有多种表现形式,因此诊断往往延迟。此外,考虑到其罕见性以及心脏位置本身带来的限制,原发性心脏肉瘤患者的最佳多模式管理仍然非常困难,预后不佳。因此,迫切需要改善这些结果,主要侧重于更合适的快速诊断工具,并探索新的、更有效的治疗方法。由于这种疾病的罕见性,关于心脏肉瘤的分子格局和发病机制的知识更加有限。从这个意义上说,心脏肿瘤的分子特征可能揭示潜在的新型可药物靶点。在本综述中,我们专注于心脏肉瘤的基因畸变和分子生物学,收集现有的稀缺信息,并总结在每种肿瘤亚型中发现的所有分子研究结果,旨在进一步深入了解肿瘤生长所涉及的机制,并可能突出特定的分子特征,这些特征可用于诊断测试,并揭示这种棘手且具有挑战性的疾病中新的临床可操作靶点。